Delivering the Promise of Extracellular Vesicle Therapeutics

We’re developing oral, gut-restricted, multi-specific immunotherapies based on next generation extracellular vesicle technology to address critical unmet clinical needs in gastrointestinal diseases

See Our Science

See Our Science

See Our Science

Our Mission

Our Mission

From Microbes to Biotherapeutics

From Microbes to Biotherapeutics

At Expora, were leveraging recent scientific breakthroughs revealing how the gut microbiome communicates with human tissues - through Extracellular Vesicles (EVs). Our platform produces potent, GI-stable EVs from beneficial, proven-safe bacteria at 100× lower costs than conventional EV approaches. A modular design lets us rapidly configure new EV candidates for oral delivery of biologics that engage clinically-validated targets in intestinal inflammation and repair.

At Expora, were leveraging recent scientific breakthroughs revealing how the gut microbiome communicates with human tissues - through Extracellular Vesicles (EVs). Our platform produces potent, GI-stable EVs from beneficial, proven-safe bacteria at 100× lower costs than conventional EV approaches. A modular design lets us rapidly configure new EV candidates for oral delivery of biologics that engage clinically-validated targets in intestinal inflammation and repair.

Meet EXP-114

Meet EXP-114

Redefining IBD Treatment

EXP-114 is a next-generation oral EV therapy that targets underlying causes of multiple GI diseases by enhancing the body's own protective mechanisms. Built on decades of research, EXP-114 targets multiple key immune pathways to restore normal mucosal immune function, for initial applications in inflammatory bowel diseases (IBD).

  • Oral delivery for patient-friendly dosing. No injections.

    Oral delivery for patient-friendly dosing. No injections.

  • Gut-targeted, multi-specific immune engagement

    Gut-targeted, multi-specific immune engagement

  • Proprietary manufacturing for unmatched potency, consistency, and scalability

    Proprietary manufacturing for unmatched potency, consistency, and scalability

  • Strongly differentiated, novel mechanism of action

    Strongly differentiated, novel mechanism of action

Learn More

Learn More

Meet EXP-114

Redefining IBD Treatment

EXP-114 is a next-generation oral EV therapy that targets underlying causes of multiple GI diseases by enhancing the body's own protective mechanisms. Built on decades of research, EXP-114 targets multiple key immune pathways to restore normal mucosal immune function, for initial applications in inflammatory bowel diseases (IBD).

  • Oral delivery for patient-friendly dosing. No injections.

  • Gut-targeted, multi-specific immune engagement

  • Proprietary manufacturing for unmatched potency, consistency, and scalability

  • Strongly differentiated, novel mechanism of action

Learn More


Our Vision

Our Vision

Our Vision

The Expora Platform™ overcomes critical EV manufacturing barriers to deliver a transformative new modality for GI disease mangement.

Platform

Platform

Platform

Lead candidate EXP-114 delivers multi-specific immunomodulatory compounds to the GI tract to heal mucosal wounds and restore normal immunity.

Pipeline

Pipeline

Pipeline

We’re actively engaging partners and early investors to advance our EV pipeline through IND-enabling studies. Get in touch to review data and plan next steps.

Partnering

Partnering

Partnering